cheka.
17th January 2019, 10:19 AM
i suspect this is cover for the andrenochrome (sp?)
https://www.thehour.com/technology/businessinsider/article/For-8-000-this-startup-will-fill-your-veins-10860486.php
A controversial startup that charges $8,000 to fill your veins with young blood now claims to be up and running in 5 cities across the US
A startup called Ambrosia that charges $8,000 to fill your veins with the blood of young people is now accepting PayPal payments for the procedure online.
Jesse Karmazin, a Stanford graduate who founded Ambrosia, told Business Insider this week that the company was up and running in five US cities.
Ambrosia recently completed its first clinical trial designed to assess the benefits of the procedure, but it has yet to publish the results. Karmazin previously told Business Insider the company wanted to open the first clinic in New York City, but that didn't happen.
To Jesse Karmazin, a startup founder and Stanford Medical School graduate, blood is the next big government-approved drug.
Roughly three years ago, Karmazin launched Ambrosia, a startup that fills the veins of older people with blood from younger donors, hoping the procedure would help conquer aging by rejuvenating the body's organs. As Business Insider previously reported, there's little to no evidence to suggest this would work.
https://www.thehour.com/technology/businessinsider/article/For-8-000-this-startup-will-fill-your-veins-10860486.php
A controversial startup that charges $8,000 to fill your veins with young blood now claims to be up and running in 5 cities across the US
A startup called Ambrosia that charges $8,000 to fill your veins with the blood of young people is now accepting PayPal payments for the procedure online.
Jesse Karmazin, a Stanford graduate who founded Ambrosia, told Business Insider this week that the company was up and running in five US cities.
Ambrosia recently completed its first clinical trial designed to assess the benefits of the procedure, but it has yet to publish the results. Karmazin previously told Business Insider the company wanted to open the first clinic in New York City, but that didn't happen.
To Jesse Karmazin, a startup founder and Stanford Medical School graduate, blood is the next big government-approved drug.
Roughly three years ago, Karmazin launched Ambrosia, a startup that fills the veins of older people with blood from younger donors, hoping the procedure would help conquer aging by rejuvenating the body's organs. As Business Insider previously reported, there's little to no evidence to suggest this would work.